Physicians' Academy for Cardiovascular Education

Real-world data PCSK9 inhibitors show same LDL-c reductions, but more side effects

Proprotein convertase subtilisin / Kexin 9 inhibition in patients with Familial Hypercholesterolemia: initial clinical experience

Literature - Galema-Boers JMH, Lenzen MJ, Sijbrands EJ and Roeters van Lennep JE - J Clin Lipidol 2017; 11(3):674-681

Main results


PCSK9 inhibitors in real-world setting showed similar LDL-c reductions as those observed in randomized clinical trials. However, side effects, especially flu-like symptoms, as well as injection site-reactions were reported more often compared to clinical trials. These findings emphasize the need to establish clinical registries to monitor the long-term efficacy and side effects of PCSK9 inhibitors outside randomized clinical trials.


Show references

Find this article online at J Clin Lipidol.

Share this page with your colleagues and friends: